Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 1.00 |
| ▸ | ACACA | Q13085 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459079 | 1.00 | ACACB (1.00) | ACACBACACAMEN1KMT2AL3MBTL3 | |
| Hydrochloric Acid SCHEMBL6181697 | 0.99 | ACACB (0.98) | ACACBACACAMEN1KMT2AL3MBTL3 | |
| SCHEMBL6182670 | 0.96 | ACACB (0.93) | ACACBACACAMEN1KMT2AL3MBTL3 | |
| SCHEMBL977641 | 0.93 | ACACB (0.86) | ACACBACACACHRM3 | |
| SCHEMBL977639 | 0.93 | ACACB (0.86) | ACACBACACACHRM3 | |
| SCHEMBL6183505 | 0.92 | ACACB (0.84) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL976349 | 0.91 | ACACB (0.83) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL2622325 | 0.91 | ACACB (0.83) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL6181556 | 0.89 | ACACB (0.80) | ACACBACACA | |
| SCHEMBL6491415 | 0.88 | ACACB (0.78) | ACACBACACAL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192080-A1 | METHODS OF TREATING, PREVENTING, AND/OR AMELIORATING CANCER WITH ACETYL COENZYME A (COA) CARBOXYLASE INHIBITOR(S) | YALE UNIVERSITY (US) | 2024-09-19 | — | — | WO | claimed |
| EP-4408980-A2 | LINEAGE SPECIFICATION DURING STEM CELL TRANSITION | Amniotics AB (SE) | 2024-08-07 | — | — | EP | claimed |
| WO-2023052650-A2 | LINEAGE SPECIFICATION DURING STEM CELL TRANSITION | AMNIOTICS AB (SE) | 2023-04-06 | — | — | WO | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| US-20210137934-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| EP-2150265-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | Neuera Pharmaceuticals, Inc. (US) | 2010-02-10 | — | — | EP | claimed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | claimed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| EP-4611792-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-119732910-A | SiRNA nano liposome and application thereof in preparation of drugs for treating non-alcoholic fatty liver disease | 浙江工业大学 | 2025-04-01 | — | — | CN | disclosed |
| WO-2024192080-A1 | METHODS OF TREATING, PREVENTING, AND/OR AMELIORATING CANCER WITH ACETYL COENZYME A (COA) CARBOXYLASE INHIBITOR(S) | YALE UNIVERSITY (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4408980-A2 | LINEAGE SPECIFICATION DURING STEM CELL TRANSITION | Amniotics AB (SE) | 2024-08-07 | — | — | EP | disclosed |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008137435-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | ACACB 1431/4885ACACA 1244/4885MEN1 3434/4885 |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885MEN1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.